Form 4 for SLS SELLAS Life Sciences Group, Inc.
Accepted 2025-11-21 00:00:00 ET · period of report 2025-11-19 · accession 0001104659-25-114806 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-11-21 | 2025-11-19 | SLS | Kalin Katherine Bach | Dir | P - Purchase | $1.59 | +63.4K | 104.4K | +155% | +$100.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-11-19 | P | A | 63,400 | $1.59 | 104,400 | D | — | — | (F1) The price reflects the weighted average purchase price of the shares of common stock purchased. These shares of common stock were purchased in multiple transactions at prices ranging from $1.555 to $1.625 per share. Ms. Kalin undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares of common stock purchased at each price. |